Response Biomedical (V.RBM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Response Biomedical (V.RBM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dick Martin who wrote (431)	3/28/2002 12:16:55 PM
From: Blaine	Read Replies (1) of 655

RESPONSE BIOMEDICAL ON CBC NEWSWORLD Vancouver, British Columbia, March 27, 2002 - Response Biomedical Corp. (RBM: CDNX) advises that Bill Radvak, President and CEO will appear today on CBC NewsWorld. Mr. Radvak discusses the significance of today's announcement in relation to the RAMP Anthrax Test. Independent U.S. government research confirms the Company's anthrax test is world's only reliable and sensitive rapid on-site screening test for the detection of anthrax. The interview is scheduled to be televised today at 3:30 and 9:30 pm Pacific Standard Time on channel 26. The interview may also air on the 6 pm news broadcast on CBC television (channel 3) in the Western region. About Response Biomedical Corp. Response Biomedical develops rapid on-site diagnostic tests for use with its proprietary RAMP Reader intended for both clinical and environmental applications, such as tests for the detection of heart attack and biological agents including anthrax. The RAMP System consists of a portable fluorescence reader and disposable test cartridges. This platform technology delivers accurate and reliable results in less than fifteen minutes, and has the potential to be used with more than 250 medical and non-medical tests currently performed in laboratories. On January 8, 2002, the U.S. Food and Drug Administration provided marketing clearance for Response Biomedical's RAMP Reader for general clinical use, and also the Myoglobin test - a cardiac marker used in the early diagnosis of heart attack. Approval in Canada is pending, and two other cardiac markers are in late-stage development. Response Biomedical's shares are listed on the Canadian Venture Exchange under the trading symbol "RBM". For further information, visit the Company's website at www.responsebio.com. Did you get a TV yet Dick? Blaine

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next